» Articles » PMID: 38127178

Current Non-invasive Strategies for Brain Drug Delivery: Overcoming Blood-brain Barrier Transport

Overview
Journal Mol Biol Rep
Specialty Molecular Biology
Date 2023 Dec 21
PMID 38127178
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The blood-brain barrier (BBB) is a complex and dynamic structure that serves as a gatekeeper, restricting the migrations of most compounds and molecules from blood into the central nervous system (CNS). The BBB plays a crucial role in maintaining CNS physiological function and brain homeostasis. It can protect the CNS from the entrance of toxic and infectious agents, however, it also restricts the drug permeation into brain to play a therapeutic role. The BBB has been the biggest limiting hurdle to medications entering the brain excluding from the brain about 100% of large-molecule and more than 98% of all small-molecule neurotherapeutics. As a result, it is of inability for drug molecule to reach requisite concentrations within the brain.

Objective: With the aim of enhancing drug permeability and efficacy, a variety of strategies have been developed: invasive approaches, such as intraarterial delivery, intrathecal delivery, or administrating directly the drug intraventricularly and intracerebrally; non-invasive approaches that take advantage of innate BBB functions, using prodrugs, focused ultrasound, intranasal administration or nanotechnology.

Conclusions: Here we mainly review recent developments and challenges related to non-invasive BBB-crossing techniques, whose benefits include higher efficacy, easier application, less treatment burden, better patient acceptability, and adherence. Additionally, we also analyze the potential of non-invasive methods in the treatment of CNS disorders and render them as a most suitable platform for the management of neurological diseases.

Citing Articles

Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis.

Li Y, Liu R, Zhao Z Pharmaceutics. 2025; 17(1).

PMID: 39861756 PMC: 11769103. DOI: 10.3390/pharmaceutics17010109.


The Crucial Role of the Blood-Brain Barrier in Neurodegenerative Diseases: Mechanisms of Disruption and Therapeutic Implications.

Kim S, Jung U, Kim S J Clin Med. 2025; 14(2).

PMID: 39860392 PMC: 11765772. DOI: 10.3390/jcm14020386.


A comprehensive neuroimaging review of the primary and metastatic brain tumors treated with immunotherapy: current status, and the application of advanced imaging approaches and artificial intelligence.

Liu X, Chen H, Tan G, Zhong L, Jiang H, Smith S Front Immunol. 2024; 15():1496627.

PMID: 39669560 PMC: 11634813. DOI: 10.3389/fimmu.2024.1496627.


Engineered Antibodies as Cancer Radiotheranostics.

Wei Z, Li B, Wen X, Jakobsson V, Liu P, Chen X Adv Sci (Weinh). 2024; 11(30):e2402361.

PMID: 38874523 PMC: 11321656. DOI: 10.1002/advs.202402361.

References
1.
Obermeier B, Daneman R, Ransohoff R . Development, maintenance and disruption of the blood-brain barrier. Nat Med. 2013; 19(12):1584-96. PMC: 4080800. DOI: 10.1038/nm.3407. View

2.
Abbott N, Ronnback L, Hansson E . Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2005; 7(1):41-53. DOI: 10.1038/nrn1824. View

3.
Sweeney M, Sagare A, Zlokovic B . Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol. 2018; 14(3):133-150. PMC: 5829048. DOI: 10.1038/nrneurol.2017.188. View

4.
Liebner S, Dijkhuizen R, Reiss Y, Plate K, Agalliu D, Constantin G . Functional morphology of the blood-brain barrier in health and disease. Acta Neuropathol. 2018; 135(3):311-336. PMC: 6781630. DOI: 10.1007/s00401-018-1815-1. View

5.
Teleanu R, Preda M, Niculescu A, Vladacenco O, Radu C, Grumezescu A . Current Strategies to Enhance Delivery of Drugs across the Blood-Brain Barrier. Pharmaceutics. 2022; 14(5). PMC: 9145636. DOI: 10.3390/pharmaceutics14050987. View